Yes, Casgevy Treats Sickle Cell Disease
Casgevy (exagamglogene autotemcel) is FDA-approved for sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises.[1] It's a one-time CRISPR/Cas9 gene therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics that edits a patient's own hematopoietic stem cells to produce high levels of fetal hemoglobin, reducing sickling of red blood cells and crises.[2]
How Casgevy Works for Sickle Cell
The therapy extracts the patient's stem cells, uses CRISPR to disable the BCL11A gene (which suppresses fetal hemoglobin), and reinfuses the edited cells after chemotherapy conditioning. Clinical trials showed 96% of SCD patients free from severe vaso-occlusive crises for at least 12 months post-infusion.[3]
Casgevy for Beta-Thalassemia Too
Casgevy also treats transfusion-dependent beta-thalassemia in patients 12 and older, with 93% achieving transfusion independence for at least a year in trials.[1] It's the same therapy addressing hemoglobin disorders.
Who Qualifies and Treatment Process
Eligible SCD patients have had 2+ crises per year. Process takes 7-10 months: cell collection, editing, myeloablative conditioning (chemo to clear bone marrow), and infusion. Requires specialized centers; over 50 authorized in the US.[2]
Cost and Access Challenges
List price is $2.2 million per patient, the highest for any drug. Coverage varies; some insurers approve for severe cases, but high costs limit access. No patient assistance program yet.[4]
Side Effects Patients Report
Common risks include chemotherapy effects (nausea, infertility risk), low blood counts, and infections. Long-term data limited; 20% experienced graft failure in trials.[3] Patients note hospital stays of weeks and recovery months.
When Did FDA Approve It and What's Next
Approved December 2023 for SCD (first CRISPR therapy cleared).[1] EU approval followed in 2024. Pediatric data expected 2025; biosimilars unlikely soon due to complex manufacturing.
Alternatives to Casgevy
- Approved gene therapies: None direct rivals; Lyfgenia (lovotibeglogene autotemcel) also FDA-approved for SCD in late 2023, similar $3.1M price.[5]
- Standard care: Hydroxyurea, transfusions, voxelotor (Oxbryta), crizanlizumab (Adakveo).
- Pipeline: CTX001 follow-ups, EDIT-301 (Bluebird bio).
[1]: FDA Approval Summary for Casgevy
[2]: Vertex Prescribing Information
[3]: NEJM Trial Results
[4]: ICER Cost Report
[5]: FDA Lyfgenia Approval